|
Synonyms: KB-004 | KB004
Compound class:
Antibody
Comment: Fibatuzumab is a humanised monoclonal antibody directed against the ephrin receptor A3 (EPHA3) [6], which is a receptor tyrosine kinase implicated in mediating nervous system development [2,7-8].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST searches of patented peptide sequences using the variable domains of the light and heavy chain sequences of fibatuzumab reveal exact matches with sequences submitted with patent US8664365 B2 [6]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C et al.. (2013)
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell, 23 (2): 238-48. [PMID:23410976] |
|
2. Flanagan JG, Vanderhaeghen P. (1998)
The ephrins and Eph receptors in neural development. Annu Rev Neurosci, 21: 309-45. [PMID:9530499] |
|
3. Guan M, Liu L, Zhao X, Wu Q, Yu B, Shao Y, Yang H, Fu X, Wan J, Zhang W. (2011)
Copy number variations of EphA3 are associated with multiple types of hematologic malignancies. Clin Lymphoma Myeloma Leuk, 11 (1): 50-3. [PMID:21454190] |
|
4. Keane N, Freeman C, Swords R, Giles FJ. (2012)
EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Rev Hematol, 5 (3): 325-40. [PMID:22780212] |
|
5. Lu CY, Yang ZX, Zhou L, Huang ZZ, Zhang HT, Li J, Tao KS, Xie BZ. (2013)
High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma. Oncol Rep, 30 (5): 2179-86. [PMID:23970317] |
|
6. Luehrsen K, Martinez D, Yi C, Bebbington CR, Yarranton GT. (2014)
Antibodies to EphA3. Patent number: US8664365 B2. Assignee: Kalobios Pharmaceuticals, Inc.. Priority date: 14/08/2009. Publication date: 04/03/2014. |
|
7. Wilkinson DG. (2000)
Eph receptors and ephrins: regulators of guidance and assembly. Int Rev Cytol, 196: 177-244. [PMID:10730216] |
|
8. Wilkinson DG. (2001)
Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci, 2 (3): 155-64. [PMID:11256076] |
|
9. Xi HQ, Wu XS, Wei B, Chen L. (2012)
Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol, 47 (7): 785-94. [PMID:22350700] |
